Literature DB >> 28984727

Sickle cell disease and the eye.

Brian K Do1, Damien C Rodger.   

Abstract

PURPOSE OF REVIEW: To review recent literature pertaining to sickle cell retinopathy (SCR) and, in particular, sickle cell maculopathy. RECENT
FINDINGS: Several recent studies suggest that macular perfusion abnormalities seen in patients with sickle cell disease of various genotypes may affect both the superficial and deep capillary plexi, with a predilection for the deep capillary plexus. Further, these changes may be associated with areas of macular thinning, as well as with peripheral retinal ischemia, even in individuals without visual symptoms, contrary to what has previously been described in both diabetic retinopathy and retinal vein occlusion. Several cases also suggest that paracentral acute middle maculopathy may be the pathophysiologic mechanism by which microvascular occlusion leads to macular thinning.
SUMMARY: Sickle cell disease can manifest in a number of ways within the orbit as well as intraocularly because of its nonspecific vasoocclusive episodes. However, SCR is the most common ophthalmic manifestation of this disease. Historically, SCR has been considered a peripheral retinopathy, but the development and use of spectral-domain optical coherence tomography and optical coherence tomography angiography suggest that significant macular vascular changes occur early in this disease, even in asymptomatic individuals.

Entities:  

Mesh:

Year:  2017        PMID: 28984727     DOI: 10.1097/ICU.0000000000000423

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  9 in total

1.  Morphine promotes neovascularizing retinopathy in sickle transgeneic mice.

Authors:  Kalpna Gupta; Chunsheng Chen; Gerard A Lutty; Robert P Hebbel
Journal:  Blood Adv       Date:  2019-04-09

2.  Control of retinal blood flow levels by selected combinations of cervical arterial ligations in rat.

Authors:  Norman P Blair; Sophie Leahy; Mahnaz Shahidi
Journal:  Exp Eye Res       Date:  2020-06-02       Impact factor: 3.467

3.  Multifocal electroretinogram findings in sickle cell maculopathy.

Authors:  Laurence Beral; Marc Romana; Nathalie Lemonne; Yoann Garnier; Marie Billaud; Malik Acomat; Coralie Zorobabel; Maryse Etienne-Julan; Thierry David; Philippe Connes
Journal:  Eye (Lond)       Date:  2019-07-09       Impact factor: 3.775

4.  Incidence of eye complications among sickle cell disease patients in Jeddah, Saudi Arabia: A cross-sectional study.

Authors:  Eid Ayed Almasoudi; Sultan Fahad Magliah; Abubakr Salem Alzwaihri; Abdullah Omar Aljuwaybiri; Abdullah Saleh Alqahtani
Journal:  Ann Med Surg (Lond)       Date:  2022-06-21

5.  Monitoring retinal pathology and cerebral injury in sickle cell disease using spectral-domain optical coherence tomography in pediatric patients.

Authors:  Jing Jin; Vinay Kandula; Robin E Miller
Journal:  Pediatr Blood Cancer       Date:  2021-03-31       Impact factor: 3.838

6.  Retinal Oxygen Delivery, Metabolism and Extraction Fraction and Retinal Thickness Immediately Following an Interval of Ophthalmic Vessel Occlusion in Rats.

Authors:  Norman P Blair; Michael R Tan; Anthony E Felder; Mahnaz Shahidi
Journal:  Sci Rep       Date:  2019-05-30       Impact factor: 4.379

7.  The Impact of Optical Coherence Tomography in the Early Identification of Children with Sickle Cell Retinopathy.

Authors:  Ashraf Abdelkader; Mohamed Shaaban; Mahmoud M Zahran; Mostafa F Mohammed; Anas M Ebrahim; Ahmed I Galhoom
Journal:  Int J Clin Pract       Date:  2022-08-29       Impact factor: 3.149

Review 8.  Surgical and Medical Perioperative Management of Sickle Cell Retinopathy: A Literature Review.

Authors:  Harrish Nithianandan; Jayanth Sridhar
Journal:  Int Ophthalmol Clin       Date:  2020

Review 9.  [Maculopathy in sickle cell disease].

Authors:  Isabel Bachmeier; Christiane Blecha; Jürgen Föll; Daniel Wolff; Herbert Jägle
Journal:  Ophthalmologe       Date:  2021-01-27       Impact factor: 1.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.